Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.60 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.60 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.60 |
| ▸ | CETP | P11597 | 1/20 | 0.54 |
| ▸ | GJB2 | P29033 | 1/20 | 0.52 |
| ▸ | GBA1 | P04062 | 1/20 | 0.51 |
| ▸ | IGF2R | P11717 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2443026 | 1.00 | MAPK1 (0.65) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL2443027 | 1.00 | MAPK1 (0.65) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL2448130 | 1.00 | MAPK1 (0.65) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL25480871 | 1.00 | MAPK1 (0.65) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL2447144 | 1.00 | MAPK1 (0.65) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL23016771 | 1.00 | MAPK1 (0.65) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL22691938 | 1.00 | MAPK1 (0.65) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL22111992 | 1.00 | MAPK1 (0.65) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL21067398 | 1.00 | MAPK1 (0.65) | MAPK1LGALS8LGALS3LGALS4CETP | |
| SCHEMBL490676 | 1.00 | MAPK1 (0.65) | MAPK1LGALS8LGALS3LGALS4CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221690-A1 | Pharmaceutical Composition for the Prevention/Treatment of Bone Disorders and a Process for the Preparation Thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (US) | 2009-09-03 | — | — | US | disclosed |
| EP-1993579-A2 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION/TREATMENT OF BONE DISORDERS AND A PROCESS FOR THE PREPARATION THEREOF | Council of Scientific and Industrial Research (IN) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007099432-A2 | PHARMACEUTICAL COMPOSITION CONTAINING BUTEA ISOFLAVONES FOR THE PREVENTION /TREATMENT OF BONE DISORDERS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221690-A1 | Pharmaceutical Composition for the Prevention/Treatment of Bone Disorders and a Process for the Preparation Thereof | SOST, BPGM, PTMS | MAPK1 2125/4885LGALS8 2656/4885LGALS3 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.